Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Rating of “Buy” from Brokerages

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has received a consensus rating of “Buy” from the eight research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and two have issued a strong buy recommendation on the company.

A number of brokerages have commented on BAYRY. Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research report on Thursday, July 2nd. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th.

Bayer Aktiengesellschaft Stock Down 5.7%

Shares of OTCMKTS BAYRY opened at $12.73 on Tuesday. The company’s 50 day moving average price is $14.02 and its 200-day moving average price is $12.51. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.67 and a current ratio of 1.04. Bayer Aktiengesellschaft has a 52-week low of $7.48 and a 52-week high of $15.23. The company has a market capitalization of $50.03 billion, a P/E ratio of -24.96, a price-to-earnings-growth ratio of 2.03 and a beta of 0.57.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.06. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. The company had revenue of $12.53 billion during the quarter, compared to analysts’ expectations of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Equities analysts forecast that Bayer Aktiengesellschaft will post 1.28 earnings per share for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a Germany-based life science company focused on health care and agriculture. Through its Pharmaceuticals, Consumer Health and Crop Science businesses, the company develops and markets products intended to improve human health, everyday self-care and agricultural productivity.

Bayer’s Pharmaceuticals business provides prescription medicines in areas such as cardiovascular disease, women’s health, oncology and specialty medicine. Its Consumer Health division offers nonprescription products in categories including pain relief, nutritional supplements, dermatology and allergy care, with brands such as Aspirin and Claritin.